stella
beta
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus — Stella
Recruiting
Back to Systemic Lupus Erythematosus trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(2 sites)
China
Wuhan Union Hospital, Wuhan, Hubei
Shanxi Bethune Hospital, Taiyuan, Shanxi
View full record on ClinicalTrials.gov